Abstract:Antibody drug conjugates (ADCs) are an emerging class of therapeutics that consist of a cytotoxic agent linked covalently to an antibody, which is directed toward a specific cell surface target expressed by tumor cells and/or the microenvironment. ADCs leverage the specificity of the antibody such that it functions as a carrier to deliver the cytotoxic payload into the tumor. Four parameters are considered critical for this class of complex engineered therapeutics: target selection, antibody, cytotoxic payload, as well as conjugation and linker technology. The development of this class of drugs has proven more complex than expected. Several challenges have arisen, including a lack of true tumor antigen specificity, early release of the cytotoxic payload into the bloodstream due to linker instability, and low potency of the payload, resulting in either greater toxicity or lack of improved efficacy compared with unconjugated cytotoxics. The approval of trastuzumab emtansine in 2013 for HER2-positive breast cancer served as a proof of concept that ADCs have therapeutic application in solid tumors. Two novel ADCs have recently been approved: trastuzumab deruxtecan for HER2-positive breast cancer and enfortumab vedotin for locally advanced or metastatic urothelial cancer. Trastuzumab deruxtecan is distinguished by a unique biochemical structure with a novel cytotoxic payload, deruxtecan-a highly potent, topoisomerase I inhibitor. Enfortumab vedotin is directed toward nectin-4 and represents an example of successful and strategic target selection. This review focuses on the concepts underlying the choice of suitable targets and novel payloads, discusses specific examples of ADCs in preclinical and clinical development, and provides future directions related to this unique class of therapeutics.

Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach

Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers

'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review

Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies

Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC

Antibody-drug conjugates in lung cancer: dawn of a new era?

The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy

Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases

Antibody-drug conjugates—an emerging class of cancer treatment

Antibody-drug conjugates for lung cancer in the era of personalized oncology

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

Antibody–drug conjugates come of age in oncology

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads

Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities

Targeting cancer with antibody-drug conjugates: Promises and challenges

A narrative review of antibody–drug conjugates in EGFR-mutated non-small cell lung cancer

Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions

Antibody-drug conjugates in solid tumors: a look into novel targets

Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer

Antibody-drug conjugates in solid tumors: a new frontier